Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GO2 trial of reduced-intensity OxCap versus best supportive care in frail or elderly advanced gastric or oesophageal cancer
ISRCTN44687907Phase 3Completed
- Sponsor
- University of Leeds
- Start
- Jan 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin and capecitabine in gastric cancer (GC), esophageal cancer and esophagogastric junction cancer (4 arms), sponsored by University of Leeds. Started Jan 2014; status: completed.
02
Drugs
oxaliplatincapecitabine
03
Conditions
gastric cancer (GC)esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on ISRCTN44687907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN44687907.